Website
News25/Ratings8
News · 26 weeks37+67%
2025-10-262026-04-19
Mix1590d
- Insider6(40%)
- Earnings3(20%)
- Other3(20%)
- SEC Filings2(13%)
- Analyst1(7%)
Latest news
25 items- PRSensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre
- INSIDERAmendment: SEC Form 4 filed by Sachetta Eric4/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Rampolla Javier4/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Martinez Magdalena3/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Martinez Magdalena4/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
- PRSensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of ContractSensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the filing of a lawsuit in the Circuit Court for the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, against SkinCure Oncology, LLC (SkinCure) alleging breach of contract related to unpaid amounts owed for Sensus products that have been delivered, accepted and deployed into clinical use. The complaint alleges that SkinCure has failed to remit millions of dollars for medical equipment that SkinCure has used since August 2025, but now refuses to p
- ANALYSTAlliance Global Partners initiated coverage on Sensus Healthcare with a new price targetAlliance Global Partners initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $7.50
- SECSEC Form 10-K filed by Sensus Healthcare Inc.10-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- INSIDERDirector Sachetta Eric bought $7,620 worth of shares (2,000 units at $3.81), increasing direct ownership by 1% to 142,113 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- PRSensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed BaseProprietary cloud-based software and add-on solution designed to provide current and future SRT-100 users with enhanced workflow, operating intelligence and clinical utility Creates a scalable, recurring-revenue opportunity for Sensus tied to treatment workflows and necessary oversight services Supports improved unit economics and expands Sensus' ability to serve Fair Deal Agreement customers and those who purchase a system Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, introduces Sensus Link, a cloud-based software and
- INSIDERSEC Form 3 filed by new insider Biscotti Larry Joseph3 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- PRSensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT TechnologyNew financing program provides a "one-stop" pathway for practices to acquire systems through outright purchase or several attractive leasing alternatives Supports improved conversion of late-stage prospects as reimbursement clarity accelerates purchase decisions and lowers breakeven point to only one patient per month Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the launch of Sensus Healthcare Financial Services, a new program intended to make it easier for dermatology practices to acquire Sensus' superficial r
- SECSensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- PRSensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer2026 CMS Physician Fee Schedule Final Rule provides a 300% per-fraction increase to delivery code that became effective January 1, 2026 Company enters 2026 with reimbursement certainty and strategic visibility, expects sequential-quarter revenue growth in Q1 and full-year profitability Shipped 14 SRT systems in Q4, most in December and none to its historically largest customer, up from six systems in Q3 excluding shipments to its historically largest customer Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for onc
- PRSensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after t
- SECSensus Healthcare Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- SECSensus Healthcare Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Sensus Healthcare, Inc. (0001494891) (Filer)
- PRSensus Healthcare to Hold Investor Meetings During JPM Week 2026 in San FranciscoSensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that management will be meeting with members of the healthcare investment community January 12–14, 2026, in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference. "With recently established coding by the Centers for Medicare & Medicaid Services validating our superficial radiotherapy for the non-invasive treatment of non-melanoma skin cancer, along with positive momentum with our Fair Deal Agreement program and an expanding international footprin
- PRSensus Healthcare Appoints Larry Biscotti to its Board of DirectorsSensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share and launching advanced imaging and oncology technologi
- INSIDERPRESIDENT AND GENERAL COUNSEL Sardano Michael was granted 40,000 shares, increasing direct ownership by 34% to 158,839 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by PRESIDENT AND GENERAL COUNSEL Sardano Michael4/A - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERDirector Sachetta Eric bought $27,510 worth of shares (7,000 units at $3.93), increasing direct ownership by 5% to 140,113 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERDirector Sachetta Eric bought $11,250 worth of shares (2,500 units at $4.50), increasing direct ownership by 2% to 133,113 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERNew insider Sachetta Eric claimed ownership of 132,706 shares (SEC Form 3)3 - Sensus Healthcare, Inc. (0001494891) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Sardano Joseph C bought $100,750 worth of shares (25,000 units at $4.03), increasing direct ownership by 2% to 1,200,293 units (SEC Form 4)4 - Sensus Healthcare, Inc. (0001494891) (Issuer)